These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36009263)

  • 21. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
    Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
    Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
    Todeschini P; Salviato E; Romani C; Raimondi V; Ciccarese F; Ferrari F; Tognon G; Marchini S; D'Incalci M; Zanotti L; Ravaggi A; Odicino F; Sartori E; D'Agostino DM; Samaja M; Romualdi C; Bignotti E
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
    De A; De A; Sharma R; Suo W; Sharma M
    J Cancer; 2020; 11(7):1927-1939. PubMed ID: 32194804
    [No Abstract]   [Full Text] [Related]  

  • 25. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer.
    Criscuolo D; Avolio R; Calice G; Laezza C; Paladino S; Navarra G; Maddalena F; Crispo F; Pagano C; Bifulco M; Landriscina M; Matassa DS; Esposito F
    Cells; 2020 Mar; 9(4):. PubMed ID: 32235572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and clinical significance of methyl-CpG binding domain protein 2 in high-grade serous ovarian cancer.
    Gong W; Ni M; Chen Z; Zheng Z
    Oncol Lett; 2020 Sep; 20(3):2749-2756. PubMed ID: 32782591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
    Huseby NE; Ravuri C; Moens U
    Free Radic Res; 2016; 50(1):1-13. PubMed ID: 26530909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis.
    Pavlič R; Gjorgoska M; Rižner TL
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
    Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
    J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.
    Matthews BG; Bowden NA; Wong-Brown MW
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.
    Han X; Gao Y; Jiang M; Li Z; Guo J; Li Y; Yi J; Hou L; Cheng J; Feng L; Jin Y; Zhao X; Yue W
    J Cancer; 2024; 15(11):3427-3440. PubMed ID: 38817863
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting DNA Repair in Ovarian Cancer Treatment Resistance.
    Wong-Brown MW; van der Westhuizen A; Bowden NA
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):518-526. PubMed ID: 32253106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M
    Gynecol Oncol; 2018 Jan; 148(1):79-85. PubMed ID: 29157627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A metabolomic approach to identifying platinum resistance in ovarian cancer.
    Poisson LM; Munkarah A; Madi H; Datta I; Hensley-Alford S; Tebbe C; Buekers T; Giri S; Rattan R
    J Ovarian Res; 2015 Mar; 8():13. PubMed ID: 25880539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
    Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
    J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.
    Wang SF; Chen MS; Chou YC; Ueng YF; Yin PH; Yeh TS; Lee HC
    Oncotarget; 2016 Nov; 7(45):74132-74151. PubMed ID: 27708226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B; Tang D; Bowden NA
    Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein.
    Kawahara B; Ramadoss S; Chaudhuri G; Janzen C; Sen S; Mascharak PK
    J Inorg Biochem; 2019 Feb; 191():29-39. PubMed ID: 30458366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.